Hyperactivated STAT3 has been demonstrated to modulate the behavior of gliomas and promote ADR and the STAT3 inhibitor pacritinib in combination with temozolimide has been shown to be effective in glioblastoma overwhelming STAT3/miR-21/PDCD4 signaling [114,115,148]. This evidence concerns the gene STAT3 and glioblastoma.